References
- Avakyan G.N.:Epidemiologiya epilepsii i optimizatsiya tera-pii fokalnykh epilepsiy [Epidemiology of epilepsy and optimization of treatment of focal epilepsies]. Epilepsiya i paroksizmal-nye sostoyaniya (Epilepsy and paroxysmal states), 2014, 1: 3–5.
- Belousova Y.D.:Effektivnost i perenosimost perampanela v kachestve dopolnitelnogo preparata upodrostkovs rezistentnoy partsialnoy epilepsiyey: rezultaty randomizirovannogo dvoyno-go slepogo platsebo-kontroliruyemogo issledovaniya, proveden-nogo v Rossiyskoy Federatsii [Efficacy and tolerability of perampanel as an add-on treatment in teenagers with refractory partial epilepsy: the results of a randomized, double-blind, placebo-controlled study conducted in the Russian Federation]. Epilep-siya i paroksizmalnye sostoyaniya (Epilepsy and paroxysmal states), 2014, 1: 27–33.
- French J.A., Krauss G.L., Biton V., Squillacote D., Yang H., Laurenza A. et al.:Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology, 2012, 79: 589–596.
- French J.A., Krauss G.L., Steinhoff B.J., Squillacote D., Yang H., Kumar D., Laurenza A. et al.:Evaluation of adjunctiveper-ampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. Epilepsia, 2013, 54: 117–125.
- French J.A., Krauss G.L., Wechsler R.T., Wang X.F., DiVentura B., Brandt C. et al.:Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy. A randomized trial. Neurology, 2015, 85: 1–8.
- Fycompa®. Package leaflet of the medicinal product for human use dated 29.06.2015. Registration number:ΛΠ-002200. International nonproprietary name: Perampanel.
- Hanada T., Hashizume Y., Tokuhara N., Takenaka O., Kohm-ura N., Ogasawara A. et al.:Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia, 2011, 52: 1331–1340.
- Karlov V.A.:Farmakorezistentnost i tolerantnost (Pharmacore-sistance and tolerance). In the book “Epilepsiya u detey i vzro-slykh zhenshchin i muzhchin. Rukovodstvo dlya vrachey” [Epilepsy in children and adult women and men. Guide for doctors]. M., Meditsina, 2010, 667–676.
- Krauss G.L., Perucca E., Ben-Menachem E., Kwan P., Shih J.J., Clément J.F. et al.:
Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: Results from phase III extension study 307 . Epilepsia, 2014, 55: 1058–1068. - Krauss G.L., Serratosa J.M., Villanueva V., Endziniene M., Hong Z., French J. et al.:Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology, 2012, 78: 1408–1415.
- Meador K.J., Yang H., Piña-Garza J.E., Laurenza A., Kumar D., Wesnes K.A.:Cognitive effects of adjunctive peram-panel for partial-onset seizures: A randomized trial. Epilepsia, 2016, 57: 243–251.
- Mula M., Kanner A.M., Schmitz B., Schachter S.:
Antiepileptic drugs and suicidality: An expert consensus statement from the Task Force on Therapeutic Strategies of the ILAE Commission on Neuropsychobiology . Epilepsia, 2013, 54: 199–203. - Patsalos P.N.:Drug Interactions With the Newer Antiepileptic Drugs (AEDs) - Part 1: Pharmacokinetic and Pharmacodynamic Interactions Between AEDs. Clinical Pharmacokinetics, 2013a, 52: 927–966.
- Patsalos P.N.:Drug Interactions with the Newer antiepileptic drugs (AEDs) - Part 2: Pharmacokinetic and Pharmacodynamic Interactions Between AEDs and Drugs Used to Treat Non-epilep-sy Disorders. Clinical Pharmacokinetics, 2013b, 52: 1045–1061.
- Patsalos P.N., Gougoulaki M., Sander J.W.:Perampanel Serum Concentrations in Adults With Epilepsy: Effect of Dose, Age, Sex, and Concomitant Anti-Epileptic Drugs. Ther Drug Monit., 2016, Jun 38 (3): 358–364. doi: 10.1097/FTD.0000000000000274.
- Renroe B., Yang H., Williams B.:Interim efficacy and safety analysis of adjunctive perampanel in the adolescent population from the extension phase of 3 double-blind, placebo-controlled phase 3 (core) studies in patients with refractory partial-onset seizures. 42nd Annual Meeting of the Child Neurology Society; 30 Oct.–2 Nov. 2013, Austin, TX, USA, 2013.
- Rogawski M.A.:RevisitingAMPA receptors as an antiepileptic drug target. Epilepsy Currents, 2011, 11: 56–63.
- Steinhoff B.J., Bacher M., Bast T., Kornmeier R., Kurth C., Scholly J. et al.:First clinical experiences with perampanel - the Kork experience in 74 patients. Epilepsia, 2014a, 55 (Suppl. 1): 16–18.
- Steinhoff B.J., Hamer H., Trinka E., Schulze-Bonhage A., Bien C., Mayer T. et al.:A multicenter survey of clinical experiences with perampanel in real life in Germany and Austria. Epilepsy Res., 2014b, 108: 986–988.
- Vlasov P.N.:Effektivnost iperenosimost: rezultaty dvoynogo sle-pogo platsebo-kontroliruyemogo i prodlennogo otkrytogo issle-dovaniya otsenki dolgovremennoy bezopasnosti i effektivnosti perampanela v RF [Efficacy and tolerability: double-blind, placebo-controlled, and extended open study to evaluate long-term safety and efficacy of perampanel in the Russian Federation]. Ep-ilepsiya i paroksizmalnye sostoyaniya (Epilepsy and paroxysmal states), 2014, 1: 10–12.